Akèy › Kansè Poumon ki pa ti selil › Kalifòni › Los Angeles
Etid klinik pou Kansè Poumon ki pa ti selil nan Los Angeles, CA
87 etid pou Kansè Poumon ki pa ti selil ap chèche patisipan nan sit nan ak bò kote Los Angeles (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Ap rekriteFaz 2
- Start Los Angeles /ID# 284999, Los Angeles
- Valkyrie Clinical Trials /ID# 271322, Los Angeles
Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial
Ap rekriteFaz 3
- Cedars-Sinai Medical Center, Los Angeles
Safety and Efficacy of OBX-115 in Advanced Solid Tumors
Ap rekriteFaz 1/2
- The Angeles Clinic and Research Institute (Melanoma), Los Angeles
- USC Norris Comprehensive Cancer Center (Melanoma/NSCLC), Los Angeles
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Ap rekriteFaz 3
- Kaiser Permanente Los Angeles Medical Center, Los Angeles
- Kaiser Permanente West Los Angeles, Los Angeles
A Study of Targeted Post-Surgery Radiation Therapy for Non-Small Cell Lung Cancer With Remaining Lymph Node Cancer After Treatment
Ap rekriteFaz 2
- USC / Norris Comprehensive Cancer Center, Los Angeles
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
Ap rekriteFaz 1
- UCLA Department of Medicine-Hematology/Oncology, Los Angeles
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Ap rekriteFaz 1/2
- UCLA Jonsson Comprehensive Cancer Center, Los Angeles
- USC Norris Comprehensive Cancer Center, Los Angeles
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
Ap rekriteFaz 3
- USC Norris Comprehensive Cancer Center ( Site 0205), Los Angeles
- UCLA Jonsson Comprehensive Cancer Center ( Site 0135), Los Angeles
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
Ap rekriteFaz 3
- Cedars-Sinai Medical Center, Los Angeles
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
Ap rekriteFaz 1
- University of California Los Angeles, Los Angeles
A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
Ap rekriteFaz 1
- Ronald Reagan UCLA Medical Center, Los Angeles
- UCLA Department of Medicine-Hematology/Oncology, Los Angeles
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung Cancer
Ap rekriteFaz 2
- START LA, Los Angeles
- Cedars-Sinai Medical Center, Los Angeles
- Valkyrie Clinical Trials, Los Angeles
A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)
Ap rekriteFaz 3
- Local Institution - 0422, Los Angeles
A Study of PHN-012 in Patients With Advanced Solid Tumors
Ap rekriteFaz 1
- PHN-012-001 Site, Los Angeles
A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
Ap rekriteFaz 1
- Research Site, Los Angeles
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
Ap rekriteFaz 3
- UCLA Clinical & Translational Research Center (CTRC) ( Site 0033), Los Angeles
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Ap rekriteFaz 3
- Oncura Health - Good Samaritan, Los Angeles
- California Research Institute, Los Angeles
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Ap rekriteFaz 2
- USC Norris Comprehensive Cancer Center, Los Angeles
- Cedars Sinai Medical Center, Los Angeles
- Valkyrie Clinical Trials, Los Angeles
Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors
Ap rekriteFaz 1
- Research Site, Los Angeles
Symbiotic-Lung-20: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
Ap rekriteFaz 1/2
- START Los Angeles, LLC, Los Angeles
- LACN Century City, Los Angeles
- Valkyrie Clinical Trials (Additional Site Pharmacy Storage Suite), Los Angeles
- ak 2 plis
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
Ap rekriteFaz 1/2
- University of Southern California, Los Angeles
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
Ap rekriteFaz 3
- UCLA Hematology/Oncology - Santa Monica, Los Angeles
Intratumoral N17350 in Advanced Solid Tumors
Ap rekriteFaz 1/2
- The Angeles Clinic and Research Institute, Los Angeles
- UCLA - Jonsson Comprehensive Cancer Center, Los Angeles
Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer
Ap rekriteFaz 2
- Research Site, Los Angeles
Qualitative Study on Detection & Tx of NSCLC in Pts w/ a History of Alcohol or SUD
Ap rekriteEtid obsèvasyon
- Los Angeles General Medical Center, Los Angeles
- USC / Norris Comprehensive Cancer Center, Los Angeles
A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors
Ap rekriteFaz 1/2
- START Los Angeles, Los Angeles
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
Ap rekriteFaz 3
- Clinical Study Site, Los Angeles
- Clinical Study Site, Los Angeles
A Study to Compare Setidegrasib (ASP3082) With Docetaxel, in People With Non-small Cell Lung Cancer With a KRAS G12D Mutation
Ap rekriteFaz 3
- UCLA Health - Santa Monica Cancer Care, Los Angeles
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
Ap rekriteFaz 1/2
- The Angeles clinic - A cedars SINAI AFFILIATE, Los Angeles
- USC Norris Comprehensive Cancer Center, Los Angeles
Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib
Ap rekriteFaz 1/2
- Valkyrie Clinical Trials, Los Angeles
TT-4 and TT-10 as Single Agents and in Combination in Subjects With Advanced Selected Solid Tumors and Pleural Mesothelioma
Ap rekriteFaz 1/2
- USC Norris Comprehensive Cancer Center, Los Angeles
Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer
Ap rekriteFaz 3
- California Research Institute, Los Angeles
- Los Angeles Cancer Network (LACN), Los Angeles
A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)
Ap rekriteFaz 2
- University of California Los Angeles - Jonsson Comprehensive Cancer Center, Los Angeles
A Phase 1 Study of EPI-326 in EGFR-mutant NSCLC and HNSCC
Ap rekriteFaz 1
- Site 105 - START Los Angeles, Los Angeles
A Study of PRMT5 Inhibitor BAY 3713372 in Participants With MTAP-deleted Solid Tumors
Ap rekriteFaz 1/2
- UCLA Health Bowyer Oncology Center, Los Angeles
A Phase 1/1b Study of IAM1363 in HER2 Cancers
Ap rekriteFaz 1
- USC Norris Comprehensive Cancer Center, Los Angeles
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Ap rekriteFaz 3
- Cedars-Sinai Medical Center, Los Angeles
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
Ap rekriteFaz 3
- UCLA Oncology Center, Los Angeles
Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations
Ap rekriteFaz 3
- Research Site, Los Angeles
FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors
Ap rekriteFaz 1
- University of Southern California, Los Angeles
A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors
Ap rekriteFaz 1
- The Angeles Clinic, Los Angeles
- UCLA, Los Angeles
Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
Ap rekriteFaz 3
- USC/Norris Comprehensive Cancer Center, Los Angeles
Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer
Ap rekriteFaz 3
- Research Site, Los Angeles
- Research Site, Los Angeles
A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer
Ap rekriteFaz 1/2
- Cedars Sinai Medical Center, Los Angeles
A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
Ap rekriteFaz 1/2
- USC/Norris Comprehensive Cancer Center, Los Angeles
Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors
Ap rekriteFaz 1/2
- USC Norris Comprehensive Cancer Center, Los Angeles
SMP-3124LP in Adults With Advanced Solid Tumors
Ap rekriteFaz 1/2
- Cedars Sinai Medical Center, Los Angeles
A Study of MGC026 in Participants With Advanced Solid Tumors
Ap rekriteFaz 1
- The Angeles Clinic and Research Institute, Los Angeles
Study of Osimertinib With Carotuximab in Advanced, EGFR-mutated Non-Small Cell Lung Cancer
Ap rekriteFaz 1
- Cedars-Sinai Cancer at The Angeles Clinic and Research Institute, Los Angeles
- Cedars-Sinai Cancer at SOCC, Los Angeles
- Cedars-Sinai Medical Center, Los Angeles
A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)
Ap rekriteFaz 1/2
- UCLA Hematology Oncology - Main Site, Los Angeles
Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors
Ap rekriteFaz 1
- UCLA - Hematology/Oncology Clinical Research Unit, Los Angeles
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
Ap rekriteFaz 1/2
- University of California Los Angeles Medical Center, Los Angeles
Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors
Ap rekriteFaz 1/2
- USC Norris Comprehensive Cancer Center, Los Angeles
AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors
Ap rekriteFaz 1
- University of California Los Angeles, Los Angeles
Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
Ap rekriteFaz 1
- University of California LA, Los Angeles
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Ap rekriteFaz 1/2
- California Research Institute, Los Angeles
- Valkyrie Clinical Trials, Los Angeles
Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers
Ap rekriteFaz 1/2
- Cedars Sinai, Los Angeles
A Study to Evaluate the Safety, Tolerability, and Efficacy of Escalating Doses of BMS-986463 in Participants With Select Advanced Malignant Tumors.
Ap rekriteFaz 1
- USC/Norris Comprehensive Cancer Center, Los Angeles
- Valkyrie Clinical Trials, Los Angeles
ILKN421H Plus Pembrolizumab in Advanced Non-Small Cell Lung Cancer
Ap rekriteFaz 2
- Valkyrie Clinical Trials, Inc, Los Angeles
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
Ap rekriteFaz 1
- Ronald Reagan UCLA Medical Center, Los Angeles
- The Regents of the University of California, Los Angeles
- UCLA Department of Medicine-Hematology/Oncology, Los Angeles
Gilteritinib for the Treatment of ALK NSCLC
Ap rekriteFaz 1
- Cedars-Sinai Medical Center, Los Angeles
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
Ap rekriteFaz 1
- USC Norris Comprehensive Cancer Center /ID# 279603, Los Angeles
Study of XB010 in Subjects With Solid Tumors
Ap rekriteFaz 1
- UCLA Department of Medicine - Hematology/Oncology, Los Angeles
A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
Ap rekriteFaz 1/2
- UCLA Medical Center, Los Angeles
A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer
Ap rekriteFaz 1/2
- The Angeles Clinic and Research Institute, Los Angeles
Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors
Ap rekriteFaz 1
- Start Lacn, Los Angeles
KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors
Ap rekriteFaz 1
- University of Southern California, Los Angeles
- Cedars-Sinai Medical Center, Los Angeles
- UCLA Department of Medicine, Los Angeles
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
Ap rekriteFaz 2
- Cedars-Sinai Medical Center, Los Angeles
BBO-11818 in Adult Subjects With KRAS Mutant Cancer
Ap rekriteFaz 1
- The Angeles Clinic and Research Institute - West Los Angeles Office, Los Angeles
DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
Ap rekriteFaz 2
- USA06-0, Los Angeles
- USA16-0, Los Angeles
Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV)
Ap rekriteFaz 3
- UCLA, Los Angeles
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
Ap rekriteFaz 2/3
- Kaiser Permanente Los Angeles Medical Center, Los Angeles
- Kaiser Permanente West Los Angeles, Los Angeles
- Cedars-Sinai Medical Center, Los Angeles
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
Ap rekriteFaz 2
- Cedars-Sinai Medical Center, Los Angeles
Comparative Effectiveness Trial of Two Supportive Cancer Care Delivery Models for Adults With Cancer
Ap rekrite
- Oncology Institute for Hope and Innovation, Los Angeles
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
Ap rekriteFaz 1/2
- Cedars-Sinai Medical Center, Los Angeles
Telisotuzumab Vedotin and Osimertinib for the Treatment of Progressive, Incurable, Non Small Cell Lung Cancer
Ap rekriteFaz 2
- UCLA / Jonsson Comprehensive Cancer Center, Los Angeles
Study of PF-07248144 in Advanced or Metastatic Solid Tumors
Ap rekriteFaz 2
- Cedars Sinai Medical Center, Los Angeles
- Cedars-Sinai Cancer at Cedars-Sinai Medical Center, Los Angeles
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
Ap rekriteFaz 1/2
- University of California Los Angeles, Los Angeles
A Study of VET3-TGI in Patients With Solid Tumors
Ap rekriteFaz 1
- USC/Norris Comprehensive Cancer Center, Los Angeles
A Phase 1 Study of CPO301 in Adult Patients With Advanced or Metastatic Solid Tumors
Ap rekriteFaz 1
- USC Norris Comprehensive Cancer Center, Los Angeles
Experiences w/ & Attitudes Towards Immune Chckpt Inhibitors in NSCLC Patients Single Center Survey Based Study
Ap rekriteEtid obsèvasyon
- Los Angeles General Medical Center, Los Angeles
- USC / Norris Comprehensive Cancer Center, Los Angeles
GEMINI-NSCLC: NSCLC Biomarker Study
Ap rekriteEtid obsèvasyon
- UCLA, Los Angeles
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
Ap rekriteFaz 1/2
- University of Southern California, Los Angeles
A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
Ap rekriteFaz 1/2
- Research Site 125, Los Angeles
- Research Site 133, Los Angeles
- Research Site 103, Los Angeles
A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression
Ap rekriteFaz 1/2
- UCLA Medical Center, Los Angeles
A Study of NX-1607 in Adults With Advanced Malignancies
Ap rekriteFaz 1
- University of Southern California, Los Angeles
A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies
Ap rekriteFaz 1/2
- The Angeles Clinic and Research Institute, Los Angeles
Etid Kansè Poumon ki pa ti selil nan lòt vil
- Houston, TX145 etid
- New York City, NY121 etid
- Arlington, VA104 etid
- Nashville, TN97 etid
- Boston, MA90 etid
- St. Louis, MO73 etid
- Chicago, IL61 etid
- Baltimore, MD60 etid
- San Antonio, TX59 etid
- Columbus, OH57 etid
- Washington, DC55 etid
- Seattle, WA53 etid
Lòt etid nan Los Angeles
- Kansè (tout kalite)74 etid
- Kansè nan tete73 etid
- Kansè pwostat61 etid
- Kansè kolorektal59 etid
- Kansè Metastatik57 etid
- Kansè ovè50 etid
- Kansè poumon45 etid
- Karsinòm selil skuamèz tèt ak kou42 etid
- Kansè pankreyas35 etid
- Kansè Endomèt34 etid
- Melanom34 etid
- Kansè tete negatif triple27 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.